17-Nov-2026 22:57:45
GUFICBIOGeneral news
GUFIC BIOSCIENCES Q2 FY27 CONCALL: TARGETS 15–20% REVENUE GROWTH, Q4 MARGIN RECOVERY & 22–25% LONG-TERM EBITDA MARGINS; EXPECTS INDORE PBT BREAKEVEN BY Q4 FY27, EUROPE ENTRY BY SEPTEMBER 2027 & US SUPPLIES IN 2028
GUFIC BIOSCIENCES LTD.